Robin A Fairhurst
4PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|May 02, 2022
Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.Robin A Fairhurst, Pascal Furet, Patricia Imbach-Weese
|Sep 15, 2020
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.Robin A Fairhurst, Thomas Knoepfel, Nicole Buschmann
|Aug 15, 2019
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.Andreas Weiss, Flavia Adler, Alexandra Buhles
|Aug 16, 2018
Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.Robin A Fairhurst, Thomas Knoepfel, Catherine Leblanc
Pageof 1
